The possibility that the high frequency of treatment failures in Indian kala-azar might be due to infection with antimony-resistant strains of Leishmania donovani has not been experimentally addressed. L. donovani isolates were obtained from splenic aspiration smears of 24 patients in Bihar, India, who either did not respond (15) ovani strains appears to be a cause of treatment failures in India.
and 1997, 34%-64% unresponsiveness was observed [4] [5] [6] [7] . A number of explanations for antimony treatment failures have been offered, including undertreatment due to an inadequate supply of the drug and immunologic or pharmacokinetic defects in the host.
The increasing number of treatment failures in India, as well as the geographic distribution of these cases, led us to consider more carefully the emergence of drug-resistant parasites as the main cause of SAG unresponsiveness in Bihar. So far as we were aware, a comparison of the SAG sensitivity of Indian isolates from responsive and unresponsive patients had not been undertaken. Although several in vitro studies of anti-leishmanial drug action or susceptibility had been performed by use of promastigotes [8, 9] , we believed that a model using intracellular infections to assay for drug sensitivity in vitro [10] [11] [12] might be more useful in revealing differences in the drug sensitivity of clinically relevant isolates. We have compared the in vitro SAG sensitivities of a large number of L. donovani isolates from Indian patients with kala-azar who were responsive or unresponsive to 1 or more full courses of SAG. A strong correlation with clinical response was revealed only when the isolates were assayed as intracellular amastigotes.
Materials and Methods
Patients. The parasite strains were isolated from 24 patients between 1995 and 1998. All patients lived within Muzzarphapur district, Bihar, India, and were parasitologically diagnosed for kalaazar by microscopic examination of splenic aspirate smears. All patients were treated with 1 (20 mg/kg daily for 30 days) or 2 courses of SAG (Albert David, Calcutta, India). The drug is pro- M  8  3  30  9848  M  14  3  30  9859  M  8  2  35  9844  M  14  3  60  9849  M  22  6  30 vided as a solution containing 333 mg of SAG/mL, 100 mg total of antimony/mL, and 0.5% (weight/volume) of phenol as a preservative. Response to treatment was evaluated by repeating splenic aspiration at day 30 of treatment. The designation of responsive patients was based on the absence of fever, clinical improvement with reduction in spleen size, and the absence of parasites in the splenic aspirate. All patients were followed up for a minimum of 6 months, and if there were no signs or symptoms of relapse, the patient was considered to be definitively cured.
Parasites. Splenic aspirates that were obtained before treatment were used as the source of material for primary culture of promastigotes. Parasites were cultivated initially at 26ЊC in triple N-agar tubes and subsequently passaged in complete M199 (M199-C), supplemented with 20% heat-inactivated fetal bovine serum (FBS; Hyclone Laboratories, Logan, UT), 100 U/mL penicillin, 100 mg/mL streptomycin, 2 mM l-glutamine, 40 mM HEPES (Calbiochem, La Jolla, CA), 0.1 mM adenine (in 50 mM HEPES), 5 mg/mL hemin (in 50% triethanolamine), and 1 mg/mL 6-biotin (in 95% EtOH), pH 7.2. Isolates were maintained by up to 5 serial passages prior to shipment to the National Institutes of Health, where frozen stocks of each isolate were prepared in Dulbecco's MEM (DMEM) supplemented with 10% FBS, 7.5% dimethyl sulfoxide, and liquid nitrogen until use. All of the isolates used in this study were typed as L. donovani on the basis of their reaction with species-specific monoclonal antibodies.
Purification of metacyclic promastigotes. The monoclonal antibody MG1, which recognizes stage-specific oligosaccharide structures on the surface lipophosphoglycan of procyclic promastigotes of L. donovani strains from India (unpublished data), was used for the negative selection of metacyclic promastigotes. Promastigotes from 5-to 6-day stationary cultures were washed in DMEM and resuspended to /mL, and MG1 ascites was added to a final 8 1 ϫ 10 dilution of 1:200. After a 30-min incubation at room temperature, agglutinated parasites were removed by low-speed centrifugation (150 g for 5 min), and the cells remaining in the supernatant were washed 2 times by centrifugation at 2100 g for 15 min at 4ЊC with DMEM. The metacyclic promastigotes were counted and their concentration adjusted for macrophage infection.
Susceptibility of intracellular amastigotes to SAG. Normal resident peritoneal cells were obtained from BALB/c mice and were resuspended at /mL in RPMI-1640 supplemented with 5 2.5 ϫ 10 10% (volume/volume) heat-inactivated fetal calf serum (Hyclone Laboratories), penicillin (100 U/mL) streptomycin (50 mg/mL), and 12.5 mM 1-glutamine (RPMI-C; Bethesda Research Laboratories, Gaithersburg, MD). The cells were plated in 0.4 mL on 8-chamber Lab-Tek tissue culture slides (Miles Laboratories, Elkhart, IN) and were allowed to adhere overnight at 37ЊC in 5% CO 2 . Nonadherent cells were removed, and the adherent macrophages were infected with promastigotes/mL at an approximate Leishmania: 6 1 ϫ 10 macrophage ratio of 3:1 in 0.3 mL of RPMI-C. After 1 h incubation at 37ЊC, free promastigotes were removed by washing with complete medium, and the cultures were incubated for an additional 72 h. At this time, different concentrations of SAG, obtained from the same commercial source as was used for patient treatment, were added to final concentrations of 2, 4, 10, 20, 30, 40, and 50 mg/mL. The cultures were incubated an additional 72 h, and the slides were fixed in absolute methanol for 5 min and stained with Diff-quick solutions (DADE International, Miami, FL). At least 200 cells were counted, to determine the percentage of macrophages infected and the number of parasites per infected cell, and the percent killing relative to untreated macrophages was calculated on the basis of the comparison of total amastigotes per 100 macrophages. Mean ED 50 and ED 90 were determined for each strain on the basis of 3 independent assays. All assays were carried out blind-the identity of each isolate as to clinical response was not known during the assay procedure.
Susceptibility of extracellular promastigotes to SAG. Logarithmic-phase promastigotes were washed with DMEM, adjusted to /mL in modified M199-C containing 10% heat-inactivated Statistical analysis. Student's unpaired t test was used to determine the statistical significance of the values obtained. .
Results

In vitro SAG sensitivity of L. donovani strains assayed as intracellular amastigotes. The characteristics of the patients
from whom the L. donovani strains used in this study were obtained are summarized in table 1. The 9 strains in the clinically responsive group were isolated from patients who responded well to 1 full course of treatment with SAG, with no relapse. The 15 strains in the unresponsive group were isolated from patients who received 1 or 2 courses of treatment with SAG without cure. These patients were subsequently treated successfully with either amphotericin B or pentamidine.
For each strain, different concentrations of the drug were tested on intracellular amastigotes growing within mouse peritoneal macrophages in vitro. To establish successful intracellular infections for use in these assays, it was necessary to infect the cells by use of promastigotes that were highly enriched for metacyclic forms. At the relatively low parasite:macrophage ratio used for infection (3:1), the percentage of infected cells prior to removal of free promastigotes was 30%-50%, with 1 or 2 parasites per infected macrophage. The infection levels remained static or increased slightly in the untreated macrophages during the subsequent 6 days of incubation. In the untreated macrophages, no significant difference was observed between the intracellular growth of the strains from SAG-responsive versus -unresponsive cases, expressed in table 2 as the number of amastigotes per 100 macrophages after 6 days.
SAG was added to the experimental wells for the final 72 h of incubation. The results from triplicate blind assays and the correlation with the clinical data are shown in table 2. The killing profiles of 8 of the 9 strains obtained from clinically responsive cases were similar. The mean ED 50 and ED 90 of the 9 strains were mg and mg SAG/mL, re-2.37 ‫ע‬ 2.6 6.36 ‫ע‬ 7.8 spectively. The killing profiles of the 15 strains obtained from non-responsive cases were far more heterogeneous and showed a mean ED 50 and ED 90 of mg and 7.38 ‫ע‬ 3.7 29.09 ‫ע‬ 11.14 SAG/mL, respectively. Thus, the amastigotes from the unresponsive strains were an average of 3 and 5 times more resistant to killing by SAG than the sensitive ones, and the differences in ED 50 and ED 90 were highly significant ( and P ! .005 P ! , respectively). .001
In vitro SAG sensitivity of L. donovani strains assayed as extracellular promastigotes. All 24 strains were assayed for their sensitivity to SAG as extracellular promastigotes, obtained from early logarithmic-phase cultures. Although these promastigotes exhibited a broad range of sensitivity to SAG, for each of the strains the promastigote ED 50 was greater than the corresponding amastigote ED 50 . When all 24 strains are considered, no correlation between promastigote and amastigote sensitivity to the drug was observed (
). More imporr ϭ .12 tantly, no significant difference was observed when promastigotes from the responsive and unresponsive strains were compared ( vs. mg/mL). 48 ‫ע‬ 22 52 ‫ע‬ 29.7
Discussion
The temporal as well as geographic concentration of antimony treatment failures in Indian kala-azar points strongly to the emergence of antimony-resistant strains, which for the first time is validated by the in vitro studies presented here. All but 1 of the clinically responsive isolates had a SAG ED 50 of р3 mg/mL and an ED 90 of р6 mg/mL. In contrast, 12/15 of the clinically unresponsive isolates had a SAG ED 50 of 13 mg/mL, and 14/15 had an ED 90 of 116 mg/mL. The 3-and 5-fold increases in the average ED 50 and ED 90 of the clinically unresponsive strains are in each case highly significant. If the single unexplained outlier in the clinically responsive series is removed from the analysis, then the difference in average ED 90 becomes almost 10-fold.
Two previous studies involving patients with kala-azar outside of India have shown a correlation between clinical response and in vitro sensitivity to antimony [11, 12] . In each of these studies the correlation was found by use of intracellular amastigotes, and in the Sudanese study [11] , the correlation was confined to this life-cycle stage. Our studies also failed to reveal a correlation when extracellular promastigotes were used. Thus, in contrast to a previous report in which L. mexicana and L. braziliensis isolates obtained from antimony-unresponsive lesions displayed relative resistance to antimony when assayed as promastigotes [9] , the antimony resistance of the visceral L. donovani strains emerging in Sudan and India appears to be expressed only by amastigotes. It is important to bear in mind, therefore, that drug selection of antimony-resistant promastigotes in vitro [reviewed in 13] may not reproduce the mechanisms of resistance operating in parasites exposed to drug pressure in the human host.
The stage specificity of SAG resistance suggests a mode of drug action that is specific to the intracellular stage of the parasite. A similar conclusion has been drawn on the basis of the finding that intramacrophage amastigotes are far more susceptible to pentavalent antimony than promastigotes [14] . In our studies, the intracellular amastigotes were 2-60-fold more sensitive to SAG than their corresponding promastigotes. A number of macrophage-dependent mechanisms of drug action have been proposed to account for this difference, such as drug uptake and concentration or bioreduction to the more toxic trivalent form [14] . Attempts to axenize amastigotes of the Indian L. donovani strains, as has been accomplished with L. donovani from Sudan [15] , are currently under way to determine whether their resistance phenotypes can be maintained in the absence of host cell-dependent effects on drug action.
